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Introduction: The use of monoclonal antibodies is one of the strategies for
targeting the specific key points of the main pathways of cancer growth
and survival, but only a few antibodies have offered a clear clinical benefit
in the treatment of non-haematological malignancies.
Areas covered: This review summarizes the general properties of monoclonal
antibodies, including structure, nomenclature and production techniques.
The antibodies approved for use in clinical practice for the treatment of
non-haematological tumors and those antibodies still being developed in
this setting are briefly described. The types of antibody fragments are
also reported.
Expert opinion: Monoclonal antibodies were initially developed in order to
avoid the cytotoxic effects of chemotherapy on healthy tissues. However anti-
bodies have not yet replaced chemotherapy agents, since the combination of
both kinds of drugs have usually appeared to achieve higher benefit com-
pared with chemotherapy alone. The research for the development of
new monoclonal antibodies aims to identify further targets and to provide
innovative antibody constructs.
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1. Introduction
IgG antibodies are large heterodimeric molecules, approximately 150 kDa and are
composed of two different kinds of polypeptide chains, known respectively as the
heavy (~ 50 kDa) and the light chain (~ 25 kDa). There are two types of light
chains, kappa (k) and lambda (l). By cleavage with enzyme papain, the Fab (frag-
ment-antigen binding) part can be separated from the Fc (fragment crystalline) part
of the molecule. The Fab fragments contain the variable domains, which consist of
three hypervariable amino acid domains responsible for the antibody specificity
embedded in constant regions.
Antibodies can target tumors by various mechanisms: i) opsonization, which trig-
gers killing by immune cells, ii) modification of innate biological processes such as
growth and apoptosis, and iii) delivery of a cytotoxic payload such as a chemother-
apy drug, catalytic toxin, radioisotope or enzyme. However an antibody, which has
a specific target expressed in tumor cells, must gain access to all viable cells within
tumors at sufficient concentrations in order to produce a maximal change in the
tumor [1,2].
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1.1 Monoclonal antibody nomenclature
The nomenclature of monoclonal antibodies is defined by the
guidelines of The American Medical Association together
with the United States Adopted Names Council [3].
The suffix used for monoclonal antibodies or fragments
is -mab. The -mab suffix stem is preceded by source identifiers:
-u- human, -o- mouse, -a- rat, -zu- humanized, -e- hamster, -i-
primate, -xi- chimera, -axo- rat/mouse and -xizu- indicating a
combination of humanized and chimeric chains.
Furthermore, the name of the antibody includes the indica-
tion of the disease, target organ system or tumor subclass
against which the antibody is used: -vir- viral, -bac- bacterial,
-lim- immune system, -les- infectious lesions, -cir- cardio-
vascular, -fung- antifungal, -ner- neurological system,
-kin- interleukin, -mul- musculoskeletal system, -os- bone,
-toxa- toxin target, -col- colon, -mel- melanoma, -mar-
mammary, -got- testis, -gov- ovary, -pr(o)- prostate and
-tum- miscellaneous tumor.
The whole name, however, is made up of three stem ele-
ments: -target-source-mab. Drug companies may, however,
place a naming prefix at the start of the name of the agent.
1.2 Monoclonal antibody production
Different techniques have been developed for the production
of monoclonal antibodies. These methods may be grouped as
tissue cultures and mouse ascitis fluid. Their choice depends
on cost and time consumption. Hybridoma technology was
developed by K€ohler and Milstein in order to obtain mono-
clonal antibodies more efficiently [4,5]. They engineered tumor
cells to be immortalized and produce the required antibodies.
Mice are immunized with the specific antigen to target by the
monoclonal antibody. The hybrid cells are obtained by the
fusion of mouse spleen cells and mouse myeloma cells, which
therefore contain genetic material from both the parent cells.
This feature allows them to produce a specific antibody and to
grow in culture indefinitely [6]. Subsequently the researchers
applied recombinant DNA technology to the development
of monoclonal antibodies with greater safety and efficacy
through chimerization and humanization [7].
Antibody production is checked by its serum titer levels in
immunized mice. Spleen cells are withdrawn as soon as the
expected level has been reached. These mouse-derived cells
are fused with the immortal myeloma cells cultured using
growth factors. The hybridoma cells are harvested and
cloned for the production of specific antibodies. The term
‘monoclonal’ implies that these clones derive from a single
hybridoma cell type.
2. Monoclonal antibodies in cancer treatment
The research into targeted drugs in cancer treatment was
prompted because chemotherapy agents lacked specificity for
the cancer cell. Monoclonal antibodies were developed for tar-
geting proteins involved in tumor biology. However they are
not always specific for the cancer cell because such proteins
may also be expressed in healthy tissues. Thus, although the
antibody has consistent specificity towards the antigen, the
specificity of the antibody or immunoconjugate for cancer
was not absolute.
Fever, chills, flushing, rash, nausea and vomiting, broncho-
spasm, etc. were the clinical toxicities observed for the murine
monoclonal antibodies, which are secondary to the interaction
with the target antigen. Another limitation is their high
immunogenicity. After only a few infusions of these murine
proteins, human anti-mouse antibody production occurs.
Furthermore, some of the target antigens on the surface of
the cancer cells and in circulation are quickly downregulated.
This phenomenon could be mediated by internalization of the
antibody--antigen complex. It has been exploited for the activ-
ity of immnoconjugates, which are monoclonal antibodies
conjugated with drugs, toxins and radioisotopes.
2.1 Approved agents
Monoclonal antibodies and immunoconjugates have shown
high applicability in hematological malignancies. They have
led to significant progress in the availability of effective treat-
ments for the management of such diseases. In this review we
discuss the use and development of monoclonal antibodies
and antibody fragments in solid tumors. So far, only a few
monoclonal antibodies have been approved for their treat-
ment: trastuzumab, bevacizumab, cetuximab, panitumumab
(Table 1).
2.1.1 Anti-VEGF
VEGF is the main mediator of neoangiogenesis. This is a
mechanism that allows tumors to grow. In fact, as soon as
the diameter of a tumor exceeds 2 mm, VEGF together
with other growth factors stimulates the formation of new ves-
sels. The production of these growth factors by cancer cells is
induced through the hypoxia-inducible transcription factor
(HIF-1) [8,9]. VEGF plays an important role in a number of
Article highlights.
. Monoclonal antibodies were developed for targeting
proteins involved in tumor biology.
. Monoclonal antibodies have provided tools for the
improvement of survival and quality of life in the
management of a great many types of cancer.
. Hybridoma technology was developed to obtain
monoclonal antibodies more efficiently.
. The clinical toxicities observed for the murine
monoclonal antibodies are secondary to the interaction
with the target antigen.
. The production of chimeric and humanized monoclonal
antibodies is an attempt to provide drugs with minimal
adverse reactions.
. Antibody fragments might overcome the structural limits
of solid tumor tissues for penetration by
conventional antibodies.
This box summarizes key points contained in the article.
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physiological processes, such as embryogenesis, skeletal
growth and wound healing [10,11]. In humans, different iso-
forms of VEGF have been identified: VEGF-A, VEGF-B,
VEGF-C, VEGF-D and placenta growth factor (PlGF).
However, VEGF-A is generally referred to as VEGF. Its func-
tions are mediated by binding to the VEGF receptors
(VEGFR1 or Flt-1, and VEGFR2 or KDR) [12].
Bevacizumab is a recombinant humanized monoclonal
IgG1 antibody developed from the murine anti-VEGF mono-
clonal antibody A4.6.1 and binds to all isoforms of VEGF
(Avastin; Genentech.) [13]. Its binding with the receptors
VEGFR1 and VEGFR2 prevents their interaction with
VEGF. Subsequently the tyrosine kinase activity of these
receptors cannot be triggered.
The inhibition of VEGF by bevacizumab leads to the
regression of the existing abnormal micro-vessels within the
tumor mass, the normalization of tumor vasculature and
the inhibition of new vessel formation [14,15]. These effects
are useful for helping chemotherapy agents reach the cancer
cells more easily. As observed in preclinical models, it is suffi-
cient to withdraw bevacizumab to obtain a rapid regrowth of
tumor vasculature. This phenomenon posed the rationale for
the continuation of bevacizumab use up to disease progression
or beyond [16].
Between 2004 and 2009 the FDA approved bevacizumab
with fluoropyrimidines for first-line and second-line
treatment for metastatic colorectal cancer, with carboplatin
and paclitaxel for first-line treatment of patients with
advanced non-squamous non-small-cell lung cancer, with
paclitaxel for first-line treatment of patients with metastatic
human EGFR 2(HER2)-negative breast cancer, as monother-
apy for recurrent glioblastoma, with interferon for first-line
therapy in metastatic renal cell carcinoma.
Two Phase III clinical trials have demonstrated improved
survival in patients with advanced colorectal cancer when bev-
acizumab was added to standard 5-fluorouracil (5-FU)-based
chemotherapy regimens, which incorporate irinotecan (irino-
tecan, 5-FU, leucovorin (IFL)) and oxaliplatin (5-FU,
leucovorin, oxaliplatin (FOLFOX4)) [17,18]. Bevacizumab in
combination with 5-FU-based chemotherapy has been shown
to be effective in both first- and second-line treatment of
advanced colorectal cancer. Moreover it is reasonable to
believe, as supported by two large observational registry
trials in first-line metastatic colorectal cancer (the Bevacizu-
mab Regimens: Investigation of Treatment Effects and
Safety (BriTE) trial in the USA and the Bevacizumab
Expanded Access Trial (BEAT) trial conducted in Europe
and Canada), that bevacizumab in combination with any
fluoropyrimidine-based chemotherapy is more effective than
any fluoropyrimidine-based chemotherapy alone [19,20].
Achievement of overall survival (OS) and progression-free
survival (PFS) benefit from the addition of bevacizumab to
Table 1. Approved monoclonal antibodies with indications for non-haematological malignancies and related
warnings for their use.
Approved drug Indications (FDA) Warnings
Bevacizumab Metastatic colorectal cancer, with intravenous 5-fluorouracil--based
chemotherapy for first- or second-line treatment
Gastrointestinal perforations
Surgery and wound healing
complications
Hemorrhage
Non-squamous NSCLC with carboplatin and paclitaxel for first line
treatment of unresectable, locally advanced, recurrent or metastatic disease
Metastatic breast cancer, with paclitaxel for treatment of patients
who have not received chemotherapy for metastatic human EGFR2
(HER2)-negative breast cancer
Glioblastoma, as a single agent for patients with progressive disease
following prior therapy
Metastatic renal cell carcinoma with IFN-a
Trastuzumab Adjuvant treatment of HER2 overexpressing early breast cancer Cardiomyopathy
Infusion reactions
Embryo--fetal toxicity
Pulmonary toxicity
Treatment of HER2 overexpressing metastatic breast cancer
Treatment of HER2-overexpressing metastatic gastric or gastroesophageal
junction adenocarcinoma
Cetuximab Locally or regionally advanced squamous cell carcinoma of the head and
neck in combination with radiation therapy
Infusion reactions
Cardiopulmonary arrest
Recurrent or metastatic squamous cell carcinoma of the head and neck
progressing after platinum-based therapy
As a single agent, EGFR-expressing, KRAS wild-type, metastatic colorectal
cancer after failure of both irinotecan- and oxaliplatin-based regimens or
in patients who are intolerant to irinotecan-based regimens
In combination with chemotherapy, EGFR-expressing, KRAS wild-type,
metastatic colorectal carcinoma in patients who are refractory to
irinotecan-based chemotherapy
Panitumumab As a single agent for the treatment of KRAS wild-type metastatic colorectal
carcinoma with disease progression on or following fluoropyrimidine,
oxaliplatin and irinotecan chemotherapy regimens
Infusion reactions
Dermatologic toxicity
Di Fede, Bronte, Rizzo, et al.
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chemotherapy is at the cost of a significant increase in toxicity.
Commonly observed adverse effects in clinical trials with bev-
acizumab included bleeding, thrombosis, hypertension, and
proteinuria. Hypertension observed in clinical trials has been
manageable with oral antihypertensives; however, frequent
monitoring of blood pressure is necessary. Some conditions
should be considered as contraindications to the use of
bevacizumab, for example, cerebral metastases, advanced
atherosclerotic disease or proteinuria. Gastrointestinal perfo-
ration and poor wound healing are more frequent with
bevacizumab, but rare [21].
There is no evidence to support the use of bevacizumab as
monotherapy in advanced colorectal cancer. There is no avail-
able evidence to answer the question of whether bevacizumab,
when used as a part of first-line therapy, should be continued
upon progression as part of a second-line regimen. Further
randomized clinical trials are required to answer this question.
A Phase III clinical trial (E4599) in patients with advanced
or recurrent stage IIIB/IV NSCLC compared chemotherapy
(carboplatin and paclitaxel) alone and the same regimen plus
bevacizumab. After completion of six cycles of treatment,
patients receiving bevacizumab with chemotherapy continued
on bevacizumab as a single agent until disease progression or
intolerable toxicities occurred. Adding bevacizumab to pacli-
taxel and carboplatin chemotherapy significantly increased
not only PFS and response rate (RR) but also OS [22].
Recently published data from the Avastin in Lung (AVAiL)
trial confirmed clinical efficacy of bevacizumab in combina-
tion with a different platinum-doublet chemotherapy (cis-
platin plus gemcitabine) in patients with stage IIIB/IV
NSCLC; however, the OS benefit favoring bevacizumab did
not reach statistical significance [23].
VEGF plays its role in the process of metastatic disease
development for breast cancer patients. The angiogenic
pathways are poorly active in the early stages of cancer [24].
For this reason it is essential to target the VEGF-associated
angiogenesis for adjuvant treatment.
In an open-label Phase III trial (E2100) of paclitaxel plus
bevacizumab versus paclitaxel alone as first-line therapy of
metastatic breast cancer, 722 patients were studied and
showed benefit for PFS and overall response rate (ORR) but
not for OS [25].
Bevacizumab was approved for use as first-line therapy in
advanced breast cancer according to these findings. Recently,
the FDA voted unanimously against this licensed indication
in the product’s labeling, since the Phase III Avasin and doce-
taxel (AVADO) (docetaxel plus placebo versus docetaxel plus
low-dose bevacizumab or high-dose bevacizumab) and Regi-
mens in Bevacizumab for Breast Oncology (RIBBON)-1
(bevacizumab plus chemotherapy or placebo plus chemo-
therapy) trials showed a statistically significant improvement
in progression-free survival, although of a much smaller
magnitude than that observed in the E2100 study [26,27].
The approval of bevacizumab for colon cancer treatment by
the FDA prompted attempts by several neuro-oncologists to
use it for recurrent malignant glioma. The first publication
of these data reported 66% radiographic responses for patients
treated with the combination of bevacizumab and irinote-
can [28]. This rate of antitumor activity is far higher than
response rates achieved with treatment with temozolomide
(5 -- 8%). These results were also confirmed in other retro-
spective analyses. Bevacizumab leads to rapid reductions in
peritumoral edema, with subsequent reduction or cessation
of corticosteroid use. This anti-VEGF monoclonal antibody
also seems to be well-tolerated, with low risk of intracranial
hemorrhage [29].
Bevacizumab for recurrent glioblastoma has been evaluated
in various prospective Phase II clinical trials as monotherapy
or in combination with irinotecan. The obtained findings
accelerated its approval by the FDA. The response rates
were 28 -- 38% for the combination and 35% for monother-
apy. The 6-months PFS rates were 43 -- 50% and 29%,
respectively. The tolerability profile was similar to that
previously reported [30,31]. Ongoing Phase III trials are evalu-
ating the combination of bevacizumab with temozolomide
and radiotherapy.
The majority of renal cell cancers (RCCs) overexpress
the HIF protein with the subsequent upregulation of the
VEGF gene [14]. A Phase III trial studied the patients with
metastatic clear-cell RCC comparing IFN-a combined with
either bevacizumab or placebo. The patients treated with the
bevacizumab combination had a significantly longer PFS
(10.2 months versus 5.4 months) and higher objective tumor
response rate (30.6 versus 12.4%). In an interim analysis,
there was no significant survival advantage. Common toxic-
ities seen in this and previous trials were hypertension,
proteinuria and a tendency to bleeding and thrombotic
events [32].
2.1.2 Anti-HER2
Trastuzumab is a humanized monoclonal antibody, which
binds the extracellular domain of the membrane receptor
HER2. This antibody is able to block the homodimerization
and the cleavage of this HER family receptor. Subsequently
the intracellular signal transduction cascade can be arrested.
Moreover other mechanisms seem to be involved in explain-
ing the molecular effects of trastuzumab. Antibody-dependent
cell-mediated toxicity is an immunological phenomenon,
which has been documented for trastuzumab as well as for
other monoclonal antibodies [33].
The HER2 gene is over-expressed in about 15 -- 20% of
breast tumors. Its expression can be detected by both the
immunohistochemical HER2 protein levels and fluorescent
in situ hybridization (FISH) or chromogenic in situ hybridiza-
tion (CISH) HER2 gene amplification. Breast cancer is
defined as HER2-positive, if the HER2 protein expression
by immunohistochemistry (IHC) has a 3+ score or if
HER2 gene amplification has a ratio of HER2 : centromere
signals ‡ 2,2. HER2 positivity is associated with higher
aggressiveness of the breast cancer, as indicated by a higher
Monoclonal antibodies and antibody fragments
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proliferation rate, the metastatic potential and angiogenesis.
HER2-positive breast cancer patients show a worse prog-
nosis, with shorter median survival, about half of that for
HER2-negative patients.
Trastuzumab has been studied in combination with che-
motherapeutic agents, such as anthracyclines, taxanes, plati-
num compounds and vinorelbine. A synergistic effect has
been observed, and in particular an enhanced cytotoxic
effect, more evident apoptosis induction and proliferation
rate reduction.
In HER2-positive untreated patients with advanced breast
cancer, trastuzumab has shown a clear benefit, when it is
added to chemotherapeutic agents, such as docetaxel, pacli-
taxel or doxorubicin-cyclophosphamide combination. These
patients experienced higher RR, time to progression (TTP)
and OS [34,35]. Subsequently trastuzumab was studied in com-
bination with other drugs. Usually trastuzumab-treated
patients develop acquired resistance, as highlighted by disease
progression within one year following the start of delivery [36].
When the patient experiences a progression during treatment
with a trastuzumab-containing regimen, the continuation of
trastuzumab is suggested with a concomitant change of che-
motherapy, based on the findings from both retrospective
and Phase III trials [37,38].
The main limitation for the clinical application of trastuzu-
mab is represented by its potential cardiotoxicity, above all
when it is combined with anthracyclines. For this reason
this combination is not recommended. Recently some
Phase II trials reported the feasibility of the combination of
trastuzumab with liposomal doxorubicin [39,40].
For the adjuvant treatment of early breast cancer, trastuzu-
mab has been tested in several studies involving more than
10,000 women. The available data, considered in their
entirety, suggest that one year of treatment with trastuzumab
is able to reduce the risk of relapse by about 50% [41]. The
duration of treatment for one year has been chosen empiri-
cally, arguing that trastuzumab needs to be delivered for a
long time to be efficacious. Up till now this duration is con-
sidered standard, even though some studies have highlighted
similar benefit for shorter periods of administration [42,43].
A longer delivery of trastuzumab for 2 years is under evalua-
tion. However the real goal is to demonstrate the equivalent
benefit deriving from a shorter duration, since it might lead
to less cardiotoxicity. Adjuvant trastuzumab is indicated for
all HER2-positive breast tumors. Its use in patients with
tumors smaller than 1 cm has not yet been clarified, since
they could not be enrolled in the clinical studies for trastuzu-
mab in the adjuvant setting. Retrospective data showed that
the overexpression of HER2 implies a worse prognosis inde-
pendent of tumor dimension. Subsequently further clinical
studies should be prompted to shed light on this aspect.
2.1.3 Anti-EGFR
Two anti-EGFR monoclonal antibodies are currently
available for the treatment of metastatic colorectal cancer
(mCRC). Cetuximab is a chimeric immunoglobulin G1 anti-
body, and panitumumab is a fully human immunoglobulin
G2 antibody.
Patients with advanced colorectal cancer respond to anti-
EGFR antibodies independently of EGFR protein expression
in tumor tissue, even though a clear explanation has not yet
been provided [44,45]. Other factors seem to be associated
with resistance to anti-EGFR monoclonal antibodies and
include ligand expression, alterations in downstream signaling
pathways, and cross-talk between different members of the
HER family [46]. However the most important predictive fac-
tor for the resistance to these drugs are somatic mutations in
the KRAS oncogene [47-50]. These mutations imply a constitu-
tive activation of the Ras/Raf/MAPK signaling pathway,
which is independent of the EGFR activation by ligand bind-
ing. KRAS mutations are observed in ~ 38% of colorectal
tumors [51,52]. Other molecular predictive factors seem to be
correlated with anti-EGFR antibodies efficacy. They include
somatic mutations of BRAF and PI3K catalytic, alpha poly-
peptide (PI3KCA) genes, the amplification of the EGFR
gene and the impaired expression of the phosphatase and
tensin homolog (PTEN) protein [53-57]. However these are
still under evaluation. The European Medicines Agency
has restricted the use of these antibodies in patients with
wild-type KRAS tumors [58].
At first, cetuximab was studied for the treatment of patients
with chemo-refractory advanced colorectal cancer. In parti-
cular cetuximab combined with irinotecan achieved a
higher response rate than cetuximab alone in a randomized
Phase II trial in patients resistant to irinotecan (22.9 versus
10.8%, p = 0.007) [45]. Median PFS and response rate were
also improved by the same combination of cetuximab and
irinotecan when compared with irinotecan alone (PFS:
4.0 versus 2.6 months, p £ 0.0001; RR: 16.4 versus 4.2%,
p < 0.0001), even though a non-significant difference was
observed for the median OS (10.7 versus 10.0 months,
p = 0.71), which was the primary endpoint of this study [59].
However this result may be a consequence of the crossover
to cetuximab, which a large number of patients in the control
arm experienced. Cetuximab showed benefit also when
administered alone as compared with best supportive care in
chemotherapy-refractory patients. In this study the median
OS was 6.1 months for cetuximab and 4.6 months for best
supportive care (p = 0.005) [60].
More recently an advantage for the use of cetuximab in
first-line treatment was demonstrated. The addition of cetux-
imab to flinic acid, 5 FU and irinotecan (FOLFIRI) versus
FOLFIRI alone in the Cetuximab Combined With Irinotecan
in First-Line Therapy for Metastatic Colorectal Cancer
(CRYSTAL) trial resulted in a modest but statistically signi-
ficant increase in the median PFS (8.9 versus 8.0 months,
p = 0.048) [61]. In the large randomized Phase II study for che-
monaı¨ve patients with metastatic colorectal cancer, they were
treated with either FOLFOX plus cetuximab or FOLFOX
alone. No statistically significant differences in median PFS
Di Fede, Bronte, Rizzo, et al.
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(7.2 months in both arms) and response rate (46 versus 36%,
p = 0.064) were observed [62]. In any case, a significantly
wider difference for RR was achieved in subjects with good
performance status (49 versus 37%, p = 0.032).
A subgroup analysis of these two randomized trials accord-
ing to KRAS status was performed [63,64]. Patients with wild-
type KRAS obtained a better outcome when cetuximab was
added to FOLFIRI or FOLFOX. The median PFS proved
to be significantly different in the two treatment arms in
KRAS-wild-type patients, but not in the KRAS-mutated
ones. Moreover the combination of FOLFOX with cetuximab
appeared harmful in the patients with KRAS mutations.
Cetuximab was also approved for the treatment of head and
neck cancer, in combination with radiotherapy for treatment
of locally advanced disease and as a single agent in patients
with advanced platinum resistant disease.
The first application was prompted by the results of a
Phase III randomized trial. A total of 424 patients were
divided into two arms: radiation therapy alone versus supple-
mentary treatment with cetuximab. At a median follow-up of
54 months, a doubling of the survival rate was observed in
patients receiving cetuximab compared with patients receiving
radiation therapy alone (49 versus 29 months; p = 0.03). Sta-
tistically significant increases in loco-regional control and PFS
were also reported for the group receiving cetuximab. This is
the first study to demonstrate a statistically significant survival
benefit rate for patients treated with curative intent using an
anti-EGFR antibody [65]. These findings led to the achieve-
ment of the combination of cetuximab with radiotherapy as
an alternative to chemo-radiotherapy in unsuitable patients.
The pivotal role of cetuximab, alone or in combination
with chemotherapy, was also studied in the treatment of
recurred or metastatic squamous-cell carcinoma of head and
neck cancer. Addition of cetuximab to cisplatin significantly
improvedRR, although PFS and OS were not significantly
improved [66]. Cetuximab plus platinum--fluorouracil chemo-
therapy was compared with the same chemotherapy regimen
alone in the Erbitux in First-Line Treatment of Recurrent or
Metastatic Head and Neck Cancer (EXTREME) study, a
Phase III trial for patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck. The first-
line treatment with combination improved overall survival
(hazard ratio (HR) for death, 0.80; p = 0.04) and all the other
endpoints [67].
A Phase III trial evaluated single-agent panitumumab ver-
sus best supportive care (BSC) in patients with chemorefrac-
tory (100 and 37% of the patients had received two and
three lines of previous treatment, respectively) advanced colo-
rectal cancer, which expressed EGFR regardless of the KRAS
mutational status. Panitumumab reduced the risk of disease
progression compared with BSC alone by almost half
(HR = 0.54, 95% CI: 0.44 -- 0.66, p < 0.0001) [68]. The group
of patients bearing a KRAS mutation achieved no clinical
responses when treated with panitumumab, whereas those
with wild-type KRAS achieved a 17% ORR, as a result of
the treatment with panitumumab [47]. It is interesting to
note that among patients in the control arm who crossed
over to receive panitumumab after progression, RR was
11% with an additional 33% of patients achieving stable
disease (SD) [69].
2.2 Agents in development
During the last year about ten monoclonal antibodies have been
under evaluation in Phase III trials for the treatment of solid
tumors. Among these, unmodified, conjugated and radiolabeled
antibodies are included. They target various antigens: HER
family receptors (pertuzumab, zalutumumab), IGF-1R (dalotu-
zumab, figitumumab), VEGF-R2 (ramucirumab), cytotoxic
T lymphocyte antigen 4 (CTLA-4) (ipilimumab), etc. [70].
In this review we only report three antibodies under devel-
opment for cancer treatment, which prove to be more
interesting for this discussion.
2.2.1 Edrecolomab
Edrecolomab is a murine monoclonal antibody directed
against the transmembrane glycoprotein epithelial cell adhe-
sion molecule (EpCAM). This antigen is normally expressed
on many human epithelia and overexpressed in many
malignancies, including colorectal cancer.
Preclinical data have demonstrated its effect on antibody-
dependent cell-mediated cytotoxicity. Early clinical data dem-
onstrated antitumor activity, even in patients with advanced
disease [71]. However this antibody was included in a small
Phase III trial in patients with resected stage III colorectal can-
cer, before efficacy in patients with advanced disease was
formally demonstrated [72].
The authors of this study concluded that edrecolomab
yielded a significant improvement of relapse-free and overall
survival, similar to that observed for FU plus leucovorin.
Based on these findings, edrecolomab was approved for adju-
vant therapy in colon cancer in Germany. Four large prospec-
tive randomized trials were prompted in patients with stage II
and III colon cancer to confirm the results of this pivotal
trial [73-76].
Two of these trials compared edrecolomab alone with no
treatment in stage II disease and the others edrecolomab alone
versus chemotherapy with 5-FU plus leucovorin or the com-
bination of chemotherapy and edrecolomab in stage III colon
cancer. These studies showed a lack of efficacy of edrecolomab
in the adjuvant setting of colon cancer patients.
2.2.2 Pertuzumab
Pertuzumab is the first in a class of HER2 dimerization inhib-
itors. Binding to HER-2 inhibits its dimerization with other
HER receptors and this is thought to result in slower tumor
growth [77]. This antibody is under evaluation for the
‘trastuzumab beyond progression’ approach to extend as
much as possible the efficacy of trastuzumab-based treatment.
A recent Phase II trial revealed that half the patients who
had progressed on trastuzumab achieved a clear benefit from
Monoclonal antibodies and antibody fragments
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the combination of trastuzumab with pertuzumab; RR of
24.2% (complete response rate, 7.6%; partial response rate,
16.7%) and a median PFS duration of 24 weeks [78]. The
combination appeared to be well tolerated, and no patients
were withdrawn as a result of toxicities.
Clinical Evaluation Of Pertuzumab And Trastuzumab
(CLEOPATRA) is an ongoing Phase III clinical trial for the
evaluation of trastuzumab plus chemotherapy with or without
pertuzumab for untreated HER2-positive advanced breast
cancer patients. It will provide important information about
the efficacy and safety of adding pertuzumab to one current
standard of care in patients with HER2-positive metastatic
breast cancer [79].
Pertuzumab was evaluated in almost 400 patients with
ovarian cancer who had been treated in three large Phase II
studies. It showed the enhancement of gemcitabine activity
in platinum-resistant ovarian cancer and of carboplatin activ-
ity in platinum-sensitive disease. Those patients whose cancer
had activated HER2 or low HER3 mRNA expression
appeared to benefit from pertuzumab [80].
2.2.3 Catumaxomab
Catumaxomab is a hybrid, trifunctional and bispecific mono-
clonal antibody. It combines two half antibodies of mouse
anti-EpCAM IgG2a and rat anti-CD3 IgG2b. Catumaxomab
is defined as bispecific because it can bind two different anti-
gens and trifunctional because it is active through three differ-
ent events. Preclinical studies have, in fact, shown that one
antigen binding site recognizes the EpCAM on tumor cells,
the other antigen binding site binds to CD3, a component
of the T cell receptor complex, and the Fc-fragment binds
to FcgR Type I and III-positive cells, including macrophages,
dendritic cells and NK cells [81-83].
Catumaxomab has been studied for the intraperitoneal
treatment of malignant ascites in patients with EpCAM-
positive epithelial tumors, when standard therapy is not avail-
able or no longer feasible. Treatment consists of four
constant-rate intraperitoneal infusions via intraperitoneal
catheter at doses of 10, 20, 50 and 150 µg of catumaxomab
on days 0, 3, 7 and 10 as proposed at the result of a
Phase I/II trial [84]. This treatment was compared with para-
centesis alone in a pivotal Phase II/III study [85]. Catumaxo-
mab is able to prolong puncture-free survival in patients
with malignant ascites requiring symptomatic therapeutic
paracentesis. Side effects are explained by the cytokine
release induced by the drug and are usually reversible. These
commonly include fever, chills, nausea and vomiting.
3. Antibody fragments
The efficacy of treatments in solid tumors is different from
that in hematological malignancies because of different ana-
tomical and physiological properties. Solid tumors differ
from normal tissue with regard to vasculature, interstitial fluid
pressure, cell density, tissue structure and composition and
extracellular matrix components [86]. In fact, monoclonal anti-
bodies prove to have difficulty in penetrating solid tumors.
Experimentally the tumor penetration of antibodies is gener-
ally around 0.01% of the injected dose [87]. The aim of
present-day research is the production of antibody-based mol-
ecules with optimized molecular size, valence, charge and
affinity, able to overcome the barriers in solid tumors. The
most relevant blocks of an antibody are Fab fragments
(55 kDa) and single-chain Fv (scFv; 25 kDa). These could
be used alone or as parts of larger protein constructs
(Figure 1) [88,89].
Fab fragments, obtained by proteolytic digestion of IgG,
include a single antibody light chain linked by a disulfide
bond to a heavy chain fragment consisting of the variable
region and the first heavy chain constant region. It represents
a single binding site for the antigen. (Fab)2 fragments retain
the heavy chain hinge region and are bivalent.
Single-chain Fv (scFv) are single polypeptide chains incor-
porating a heavy chain variable and a light chain variable
region, with linker polypeptidic antigens. scFv molecules can
also be engineered to incorporate a carboxy-terminal cysteine
residue, thereby enabling formation of a (scFv)2 fragment by
virtue of disulfide bridging.
A ‘diabody’ is a bivalent molecule. It is formed by two
scFvs linked noncovalently. The variable regions of one heavy
chain and the variable regions of the other light chains form
two antigen-binding sites with extensive noncovalent interac-
tion. Diabodies have rigid, compact structures, which allow a
lower separation of the two binding sites. For this reason they
prove to be ideal for bridging between cells [90].
A further possibility is a ‘minibody’ in which two scFv frag-
ments are linked by a component of the heavy-chain region
(for example CH3), resulting in a bivalent molecule [91].
In general, lower molecular weight constructs penetrate
more quickly into tumors but have shorter and lower overall
retention in tumor tissue. Increased valence generally increases
tumor uptake and specificity.
4. Conclusions
Monoclonal antibodies represent one of the most important
technological applications for the treatment of various diseases
by the binding to specific molecules. The application of these
agents for the therapy of malignancies exploits the possibility
of arresting specific pathways of cancer biology, which are
mediated by the targeted antigens. Another mode of action
of monoclonal antibodies is their role as vectors for cytotoxic
drugs or radioactive isotopes.
In solid tumors four monoclonal antibodies have already
been approved for clinical use. These have provided valid
tools for the improvement of survival and quality of life in
the management of a great many types of cancer. Very often
the benefit deriving from their delivery requires the combina-
tion with chemotherapy. For some of these monoclonal
antibodies the indication is restricted to specific subgroups
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of patients, which present particular molecular patterns.
For example, trastuzumab requires the overexpression of
HER2 to be effective and the anti-EGFR antibodies show
no efficacy in patients with KRAS or BRAF mutations.
The aim of the research in this field of drug development is
to find new antibodies for other targets and to produce differ-
ent antibody constructs. The production of chimeric and
humanized monoclonal antibodies is an attempt to provide
drugs with minimal adverse reactions. Antibody fragments
might represent an interesting way to overcome the struc-
tural limits in solid tumor tissues for penetration by
macromolecules such as conventional antibodies.
5. Expert opinion
The idea for the application of monoclonal antibodies in can-
cer treatment was originally based on the assumption that an
antibody may bind to an antigen on the cell surface of tumor
cells through its Fab and to the receptor for Fc on the immune
cells. The consequence of this binding should be the activa-
tion of the antibody-dependent cell-mediated cytotoxicity
(ADCC). The efficacy of these agents was initially explained
through the elimination of cancer cells by ADCC.
An important number of both preclinical and clinical stud-
ies has led to the awareness that other mechanisms might also
explain the antitumor activity of monoclonal antibodies. In
fact, together with ADCC, these molecules might also block
specific pathways mediated by a specific antigen. The targets
for the tumor-directed antibodies are usually products of
oncogenes; we might therefore suppose that a monoclonal
antibody is really effective against cancer when it exploits
the phenomenon of oncogene addiction. The survival of can-
cer cells may be impaired by the inactivation of a single onco-
gene, even if they contain multiple genetic and epigenetic
abnormalities. Monoclonal antibodies inhibit cancer cell
growth if they bind to oncogenic proteins expressed on the
cell surface or in the extracellular space. This finding reduced
the role of monoclonal antibodies as immunotherapy and
enhanced their role in target therapy. For example bevacizu-
mab, which binds to soluble VEGF, should not prompt
immunological phenomena against cancer cells, but this bind-
ing blocks the function of neoangiogenesis. Moreover, several
preclinical studies have highlighted the fact that bevacizumab
achieves its effect through the amelioration of tumor vascula-
ture. This mechanism allows a better penetration of cytotoxic
agents within the tumor tissue. It also explains why bevacizu-
mab has no clinical effect when it is delivered without
chemotherapy [92,93].
ADCC remains one of the modes of action for other
monoclonal antibodies, including trastuzumab, cetuximab
and panitumumab [94-96]. This consideration is based on
both direct preclinical evidence and indirect clinical deduc-
tions. However one of the most relevant problems, resulting
from the clinical research performed on monoclonal anti-
bodies, is the difficulty in identifying those which are truly
active in early phase trials such as those involving single-agent
treatments. This is a problem regarding the use of targeted
drugs compared with cytotoxic agents. The latter are usually
studied in Phase III trials if they show antitumor activity, eval-
uated through tumor shrinkage as observed by imaging tech-
niques. This method may not be valid for monoclonal
antibodies and other targeted drugs. For this reason,
Fab (Fab)2
scFv Diabody Minibody
IgG
Fc
Ag
CH
3
CH
2
CH1
CL
VL
VH
Figure 1. Antibody construct structures are related to IgG antibody structure. The different components of the molecules are
distinguished by variation of the colours of each portion.
Ag: Antigen; CH1, CH2, CH3: Constant regions of heavy chain; CL: Constant region of light chain; Fab: Fragment-antigen binding; Fc: Fragment crystalline;
VH: Variable region of heavy chain; VL: Variable region of light chain.
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widespread efforts are required to investigate the biological
effect of these agents through appropriate preclinical models,
in order to understand if their efficacy might be achieved by
single agents or by combined treatments.
The research also involves a further problem. Several drugs
prove to be ineffective in an unselected population of patients.
The identification of predictive factors for sensitivity/
resistance to these agents will help clinicians to avoid useless
treatment in those patients who would not respond because
of particular clinical or molecular characteristics. The clinical
application of these factors would lead to a more economical
use of public resources and help to spare patients from certain
side effects.
In this paper we have chosen to report as examples the
development of three new monoclonal antibodies. The choice
is based on their peculiarity.
Edrecolomab, an anti-EpCAM antibody, was studied for a
considerable time in the adjuvant setting of colorectal cancer
patients just after it was approved for use in Germany about
ten years ago. This approval was obtained on the basis of
the positive results deriving from a small clinical trial [72].
The unsuitability of that approval is now clear, but it should
lead to reflection regarding the need for extended clinical
evaluation before the inclusion of a drug in clinical practice.
Pertuzumab has been studied up till now to extend the effi-
cacy of trastuzumab beyond the tumor progression developed
during a trastuzumab-containing treatment. Undoubtedly tras-
tuzumab is a hinge of breast cancer therapy. It is, however,
inconceivable that a great deal of money should be spent in
order to develop an antibody that might merely help another
antibody to extend its own efficacy. It would be more
reasonable to search for new active monoclonal antibodies.
Catumaxomab is interesting because it is bivalent and tri-
functional. It may represent the first of a series of monoclonal
antibodies with these characteristics. However, its efficacy has
been demonstrated for loco-regional treatment only. An eval-
uation of its real usefulness should be made when it becomes
included in clinical practice.
The production of antibody fragments is a valid option for
developing new drugs. The pharmacokinetics and pharmaco-
dynamics of these agents should be carefully investigated,
since their molecular structure cannot be compared with
those of conventional monoclonal antibodies. Their typical
penetration into tumor tissue, together with their whole-
body distribution and systemic clearance might limit the
clinical application of these antibody constructs.
Finally, in our opinion, it is essential to align the develop-
ment of new monoclonal antibodies and constructs with
research involving the biological processes of tumor growth
and the mechanisms of acquired resistance induced by
various treatments.
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